COVID-19 vaccine safety: Background incidence rates of anaphylaxis, myocarditis, pericarditis, Guillain-Barré Syndrome, and mortality in South Korea using a nationwide population-based cohort study
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0297902 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Hye Su Jeong und 1 weiteren Autor:innen. Beteiligte Einrichtung: Drug Safety Monitoring Center, National Medical Center, Seoul, South Korea. Hauptthemen laut MEDLINE: Anaphylaxis, COVID-19 Vaccines, Guillain-Barre Syndrome, Myocarditis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
To properly assess an association between vaccines and specific adverse events requires a comparison between the observed and background rates; however, studies in South Korea are currently limited. Therefore, in this study, we estimated the background incidence of anaphylaxis, myocarditis, pericarditis, Guillain-Barré syndrome (GBS), and mortality in South Korea.
Methods
A retrospective cohort study was conducted using the National Sample Cohort (NSC) data. Using NSC, the background incidence rate was estimated by dividing the number of episodes during 2009–2019 by the total population by year and then multiplying by 100,000. Using Statistics Korea data, the background mortality rate was estimated by dividing the number of deaths, during 2009–2019 by the standard population for that year and then multiplying by 100,000. Using background mortality rates, we predicted mortality rates for 2021 using autoregressive integrated moving average models. Further, the expected mortality rates were compared with observed mortality rates.
Results
The age-adjusted incidence rate (AIR) of anaphylaxis increased from 4.28 to 22.90 cases per 100,000 population (p = 0.003); myocarditis showed no significant increase, changing from 0.56 to 1.26 cases per 100,000 population (p = 0.276); pericarditis increased from 0.94 to 1.88 cases per 100,000 population (p = 0.005); and GBS increased from 0.78 to 1.21 cases per 100,000 population (p = 0.013). The age-adjusted mortality rate decreased from 645.24 to 475.70 deaths per 100,000 population (p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Drug Safety Monitoring Center, National Medical Center, Seoul, South Korea.
- Department of Public Health, Korea University Graduate School, Seoul, South Korea.
- Department of Preventive Medicine, Korea University College of Medicine, Seoul, South Korea.
- Department of Epidemiology and Health Informatics Graduate School of Public Health, Korea University, Seoul, South Korea.
ORCID-Profile: Hye Su Jeong, Byung Chul Chun
Zitieren
APA
Jeong, H. S., & Chun, B. C. (2024). COVID-19 vaccine safety: Background incidence rates of anaphylaxis, myocarditis, pericarditis, Guillain-Barré Syndrome, and mortality in South Korea using a nationwide population-based cohort study. PLOS ONE. https://doi.org/10.1371/journal.pone.0297902
Vancouver
Jeong HS, Chun BC. COVID-19 vaccine safety: Background incidence rates of anaphylaxis, myocarditis, pericarditis, Guillain-Barré Syndrome, and mortality in South Korea using a nationwide population-based cohort study. PLOS ONE. 2024. doi:10.1371/journal.pone.0297902
BibTeX
@article{Jeong2024,
author = {Jeong, Hye Su and Chun, Byung Chul},
title = {COVID-19 vaccine safety: Background incidence rates of anaphylaxis, myocarditis, pericarditis, Guillain-Barré Syndrome, and mortality in South Korea using a nationwide population-based cohort study},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0297902}
}
EUVIMED